Drug Information

General Information
Drug ID
DR00332
Drug Name
Ritonavir
Synonyms
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 538, ABT; A-84538; ABBOTT-84538; ABT 538; ABT 84538; ABT-538; ABT538; Abbott 84538; DRG-0244; N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide; Norvir; Norvir (TM); Norvir (TN); Norvir Sec; RIT; RTV; Ritonavir (JAN/USAN/INN); Ritonavir [USAN]
Drug Type
Small molecular drug
Indication Human immunodeficiency virus infection [ICD11: 1C62.Z] Approved [1]
Therapeutic Class
Anti-HIV Agents
Structure
3D MOL 2D MOL
Formula
C37H48N6O5S2
Canonical SMILES
CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
InChI
InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1
InChIKey
NCDNCNXCDXHOMX-XGKFQTDJSA-N
CAS Number
CAS 155213-67-5
Pharmaceutical Properties Molecular Weight 720.9 Topological Polar Surface Area 202
Heavy Atom Count 50 Rotatable Bond Count 18
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 9
XLogP
6
PubChem CID
392622
PubChem SID
10279496 , 103244854 , 104178993 , 104616751 , 104829353 , 11528746 , 117877983 , 118048821 , 12014859 , 124658994 , 124757062 , 124801360 , 124876828 , 124892213 , 124894323 , 125163866 , 125333191 , 126592976 , 126630875 , 14766505 , 14790837 , 17422094 , 26719904 , 29215414 , 46386817 , 46392172 , 46393138 , 46505050 , 49681649 , 523930 , 53789763 , 57402349 , 583815 , 612199 , 71825024 , 7847493 , 7890279 , 79712259 , 7980525 , 8030461 , 81092847 , 822215 , 827183 , 855141 , 92308258 , 92711419 , 93166545 , 93167041 , 9449 , 99436927
ChEBI ID
CHEBI:45409
TTD Drug ID
D0ZU9R
DT(s) Transporting This Drug MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [2]
OATP2B1 Transporter Info Organic anion transporting polypeptide 2B1 Substrate [3]
P-GP Transporter Info P-glycoprotein 1 Substrate [4]
Drug-Transporter Activity Data
Drug-Transporter Activity Data P-GP Transporter Info Km = 0.8 microM LLC-PK1 cells-MDR1 [4]
References
1 Ritonavir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos. 2010 Mar;31(2-3):178-88.
3 pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J Pharmacol Exp Ther. 2010 Sep 1;334(3):1009-22.
4 MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS. 2005 Oct 14;19(15):1617-25.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.